EVIDENCE, NOT ANECDOTE

Explore the science behind
peptide research.

Search mechanisms, development status, studied protocols, safety findings and primary sources—clearly separated by level of evidence.

Tissue Research · GH AxisReviewed September 2026

Mechano Growth Factor (MGF)

MGF · IGF-1Ec · PEG-MGF

PreclinicalInvestigational — not FDA approved

A locally expressed IGF-1 splice variant; marketed MGF and PEG-MGF products have not been validated as approved human therapies.

01

Mechanism

IGF-1 splice-variant signaling associated with mechanical loading

02

Protocol studied in research

Study design shown in plain language. This is not a personal dosing recommendation.

No validated human protocolEvidence landscape
PubMed literature
Dose studiedNot established
RouteNot established
FrequencyNot established
DurationNot established
Study population

Human evidence is absent, limited or not confirmatory

Anecdotal schedules are excluded because frequency of online repetition does not establish identity, safety, or a clinically meaningful dose.

03

Community-Reported Research Schedules

Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.

Research context or phaseAmount per administrationSchedule totalFrequencyTimingAdministrationEvidence level
No consistent, clinically validated human schedule identifiedNot establishedNot establishedNo consistent patternNot establishedNot establishedNo consistent community schedule

Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.

04

Example Reconstitution Protocol

A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.

No standardized exampleA generic calculation would be misleading

No responsible standardized human reconstitution example has been established for MGF or PEG-MGF research products.

Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.

05

Cycle & Supplies Planning

Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.

Supply total not calculatedNo standardized injectable planning basis

No responsible standardized human reconstitution example has been established for MGF or PEG-MGF research products.

Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.

06

Safety signal

Human pharmacokinetics, product identity, effective exposure, and long-term systemic safety are not established.

Research context matters.

Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.

OUR METHOD

Every claim has a place
on the evidence ladder.

01

Primary sources first

Peer-reviewed trials, FDA materials, registries and original pharmacology—not social media summaries.

02

Evidence stays separated

FDA-approved, clinical-stage, early human and preclinical findings are never presented as equivalent.

03

Protocols stay in context

Route, frequency, duration and population appear together, so a study is not mistaken for personal guidance.